Following today’s DOJ legal action aimed at blocking the proposed combination of UnitedHealth’s (UNH) Optum and Amedisys (AMED), Optum has issued the following statement: “The Amedisys combination with Optum would be pro-competitive and further innovation, leading to improved patient outcomes and greater access to quality care. We will vigorously defend against the DOJ’s overreaching interpretation of the antitrust laws.”
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UNH:
- DOJ, state AGs sue to block UnitedHealth’s acquisition of Amedisys
- Department of Justice files suit to block UnitedHealth, Amedisys merger
- Justice Department sues to block UnitedHealth takeover of Amedisys
- Myriad Genetics price target lowered to $20 from $30 at TD Cowen
- CVS Health’s (CVS) New CEO Announces Leadership Changes amid Challenges at Aetna